CAPR
Price
$6.24
Change
+$0.08 (+1.30%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
281.62M
26 days until earnings call
RGNX
Price
$11.69
Change
-$0.65 (-5.27%)
Updated
Oct 17, 01:24 PM (EDT)
Capitalization
623.35M
19 days until earnings call
Interact to see
Advertisement

CAPR vs RGNX

Header iconCAPR vs RGNX Comparison
Open Charts CAPR vs RGNXBanner chart's image
Capricor Therapeutics
Price$6.24
Change+$0.08 (+1.30%)
Volume$37.81K
Capitalization281.62M
REGENXBIO
Price$11.69
Change-$0.65 (-5.27%)
Volume$200
Capitalization623.35M
CAPR vs RGNX Comparison Chart in %
CAPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CAPR vs. RGNX commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAPR is a Hold and RGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (CAPR: $6.16 vs. RGNX: $12.34)
Brand notoriety: CAPR and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CAPR: 100% vs. RGNX: 122%
Market capitalization -- CAPR: $281.62M vs. RGNX: $623.35M
CAPR [@Biotechnology] is valued at $281.62M. RGNX’s [@Biotechnology] market capitalization is $623.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $104.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CAPR’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • CAPR’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than CAPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CAPR’s TA Score shows that 5 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • CAPR’s TA Score: 5 bullish, 5 bearish.
  • RGNX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CAPR and RGNX are a good buy in the short-term.

Price Growth

CAPR (@Biotechnology) experienced а -19.16% price change this week, while RGNX (@Biotechnology) price change was +1.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.26%. For the same industry, the average monthly price growth was +15.62%, and the average quarterly price growth was +78.54%.

Reported Earning Dates

CAPR is expected to report earnings on Nov 12, 2025.

RGNX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+1.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($623M) has a higher market cap than CAPR($282M). RGNX YTD gains are higher at: 59.638 vs. CAPR (-55.362). CAPR has higher annual earnings (EBITDA): -71.78M vs. RGNX (-129.93M). RGNX has more cash in the bank: 323M vs. CAPR (123M). CAPR has less debt than RGNX: CAPR (1.04M) vs RGNX (77.7M). RGNX has higher revenues than CAPR: RGNX (156M) vs CAPR (13.4M).
CAPRRGNXCAPR / RGNX
Capitalization282M623M45%
EBITDA-71.78M-129.93M55%
Gain YTD-55.36259.638-93%
P/E RatioN/AN/A-
Revenue13.4M156M9%
Total Cash123M323M38%
Total Debt1.04M77.7M1%
FUNDAMENTALS RATINGS
CAPR vs RGNX: Fundamental Ratings
CAPR
RGNX
OUTLOOK RATING
1..100
782
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
71
Overvalued
PROFIT vs RISK RATING
1..100
93100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9392
P/E GROWTH RATING
1..100
10020
SEASONALITY SCORE
1..100
9012

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CAPR's Valuation (64) in the Biotechnology industry is in the same range as RGNX (71). This means that CAPR’s stock grew similarly to RGNX’s over the last 12 months.

CAPR's Profit vs Risk Rating (93) in the Biotechnology industry is in the same range as RGNX (100). This means that CAPR’s stock grew similarly to RGNX’s over the last 12 months.

CAPR's SMR Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that CAPR’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (92) in the Biotechnology industry is in the same range as CAPR (93). This means that RGNX’s stock grew similarly to CAPR’s over the last 12 months.

RGNX's P/E Growth Rating (20) in the Biotechnology industry is significantly better than the same rating for CAPR (100). This means that RGNX’s stock grew significantly faster than CAPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CAPRRGNX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 16 days ago
85%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 8 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
CAPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RRGTX7.420.01
+0.13%
DWS RREEF Global Real Estate Secc S
CCWIX22.57-0.03
-0.13%
Baird Chautauqua International Gr Instl
LKEQX41.06-0.15
-0.36%
LKCM Equity
JATTX27.59-0.22
-0.79%
Janus Henderson Triton T
SVPSX85.68-1.07
-1.23%
ProFunds Small Cap Value Svc

CAPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, CAPR has been loosely correlated with BEAM. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if CAPR jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAPR
1D Price
Change %
CAPR100%
-7.92%
BEAM - CAPR
35%
Loosely correlated
-5.15%
RGNX - CAPR
34%
Loosely correlated
+0.33%
ACLX - CAPR
34%
Loosely correlated
-3.81%
XNCR - CAPR
33%
Loosely correlated
+6.03%
AURA - CAPR
33%
Poorly correlated
-2.52%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+0.33%
SYRE - RGNX
55%
Loosely correlated
+0.23%
DNLI - RGNX
54%
Loosely correlated
+2.51%
KYMR - RGNX
53%
Loosely correlated
-3.86%
MGNX - RGNX
53%
Loosely correlated
N/A
VYGR - RGNX
53%
Loosely correlated
+0.76%
More